Novel drug approvals vs Antibody-drug conjugate trial starts in United States
In 2025, novel drug approvals in United States stood at 46, against 144 for antibody-drug conjugate trial starts.
Change the pair
Compare different indicators
The series
Over time
United States, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Novel drug approvals and Antibody-drug conjugate trial starts
Unit: count · 8 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Novel drug approvals | 2025 | Actual | 46 |
| Novel drug approvals | 2024 | Actual | 50 |
| Antibody-drug conjugate trial starts | 2025 | Actual | 144 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 105 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 94 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 96 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 94 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 73 |
Shared periods
Side by side
2 periods are published for both series in United States as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Novel drug approvals
Total number of novel drugs approved for the first time by a regulatory authority within a calendar year.
2 observations charted in United States · source organisations: FDA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in United States · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring